{"id":"NCT00417612","sponsor":"Yale University","briefTitle":"Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets","officialTitle":"The Role of Parathyroid Hormone in the Pathogenesis of Skeletal Disease in X-linked Hypophosphatemic Rickets (XLH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01","primaryCompletion":"2012-08","completion":"2012-08","firstPosted":"2007-01-01","resultsPosted":"2014-10-28","lastUpdate":"2020-03-17"},"enrollment":33,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypophosphatemia, Familial","Hyperparathyroidism"],"interventions":[{"type":"DRUG","name":"Paricalcitol","otherNames":["Zemplar"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the effectiveness of paricalcitol, a form of synthetic vitamin D, in lowering parathyroid hormone (PTH) levels and reducing disease symptoms in children and adults with X-linked hypophosphatemic (XLH) rickets.","primaryOutcome":{"measure":"Area Under the Curve for Parathyroid Hormone (PTHauc) Measurement","timeFrame":"Measured at baseline and Month 12","effectByArm":[{"arm":"Paricalcitol (Active Drug)","deltaMin":1223,"sd":426},{"arm":"Placebo","deltaMin":1449,"sd":865}],"pValues":[{"comp":"OG000 vs OG001","p":"0.007"}]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["12386264","2753981","25029424"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":22},"commonTop":["Elevated Serum Creatinine","Hypercalcemia"]}}